Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 159

The DOI matches its Crossref record.

Multicenter trial of low‐dose paclitaxel in patients with advanced AIDS‐related Kaposi sarcoma

Tulpule, Anil, Groopman, Jerome, Saville, M. Wayne, Harrington, William, Friedman‐Kien, Alvin, Espina, Byron M., Garces, Carlos, Mantelle, Lily, Mettinger, Karl, Scadden, David T., Gill, Parkash S. · 2002 · Cancer

Abstract

BACKGROUND: Treatment options are limited for patients with advanced acquired immunodeficieny syndrome (AIDS)‐related Kaposi sarcoma (AIDS‐KS) whose disease has progressed after receiving therapy with liposomal anthracyclines or combination chemotherapy with doxorubicin (Adriamycin), bleomycin, and vincristine (ABV). This study was performed to assess the safety and efficacy of a novel dose and schedule of paclitaxel in patients with AIDS‐KS who failed to respond to previous systemic chemotherapy. METHODS: This was an open‐label, multicenter Phase II study. Eligible patients had advanced AIDS‐KS consisting of at least 25 mucocutaneous lesions, visceral disease, or lymphedema, and had failed to respond to at least one previous systemic chemotherapy regimen. Patients were treated with paclitaxel at a dose of 100 mg/m 2 given intravenously over 3 hours, every 2 weeks. Primary efficacy end points were tumor response, time to progression, time to treatment failure, and survival. Quality of life and adverse events were evaluated using the Symptom Distress Scale (SDS) and the World Health Organization Toxicity Criteria, respectively. RESULTS: One hundred and seven male patients with advanced AIDS‐KS were enrolled from nine participating sites. The median entry CD4+ lymphocyte count was 41/mm 3 (range 0–1139). Previous treatment regimens included ABV in 52, liposomal daunorubicin in 49, and liposomal doxorubicin in 40 patients. Forty‐one patients (38%) received two or more previous chemotherapy regimens. Protease inhibitor use during the study was reported by 82 (77%) patients overall; 47 patients (44%) were receiving a protease inhibitor before study entry. Complete or partial response was documented in 60 patients (56%). The median duration of response was 8.9 months. Major response rate was similar when comparing patients not on a protease inhibitor at the time of response (59%) with patients on a protease inhibitor at time of response (54%). However, protease inhibitor use had a significant impact on survival (P = 0.04). Grade 4 neutropenia was reported in 35% of patients; other life‐threatening side effects were uncommon. Significant improvements were seen in the total quality of life scores measured by the SDS, including significant improvement in KS‐related symptoms such as facial disease, tumor‐associated edema, and pulmonary involvement. CONCLUSION: Paclitaxel given every 2 weeks induces major tumor regression in the majority of patients with advanced KS who failed to respond to previous systemic chemotherapy. Paclitaxel is associated with significant improvement in quality of life with acceptable toxicity and should be considered as an effective treatment option for patients with advanced KS. Cancer 2002;95:147–54. © 2002 American Cancer Society. DOI 10.1002/cncr.10634

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.10634

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 159

Metadata

Authors
Tulpule, A., Groopman, J., Saville, M. W., Harrington, W., Friedman‐Kien, A., Espina, B. M., Garces, C., Mantelle, L., Mettinger, K., Scadden, D. T., & Gill, P. S.
Venue
Cancer
Publisher
Wiley
Published
2002-06-28
Volume
95
Issue
1
Pages
147-154
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2081258495
Cited by
159
References
0
FWCI
3.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicenter trial of low‐dose paclitaxel in patients with advanced AIDS‐related Kaposi sarcoma. https://app.cochat.ai/papers/10.1002/cncr.10634
The paper
Tulpule, A., Groopman, J., Saville, M. W., Harrington, W., Friedman‐Kien, A., Espina, B. M., Garces, C., Mantelle, L., Mettinger, K., Scadden, D. T., & Gill, P. S. (2002). Multicenter trial of low‐dose paclitaxel in patients with advanced AIDS‐related Kaposi sarcoma. Cancer. https://doi.org/10.1002/cncr.10634

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.